Arthur Drouaud

Mr. Arthur Drouaud

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

6 November 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
RARyan Michael Antar
Ryan Michael Antar
CFChristopher Chucri Fawaz
Christopher Chucri Fawaz
DGDIEGO GONZALEZ
DIEGO GONZALEZ
VXVincent Eric Xu
Vincent Eric Xu
ADArthur Drouaud
Arthur Drouaud
MWMichael Whalen
Michael Whalen
The genetic landscape of urologic cancers has evolved with the identification of actionable mutations that impact diagnosis, prognosis, and therapeutic strategies. This narrative review consolidates existing literature on genetic mutations across key urologic cancers, including bladder, renal, prostate, upper tract urothelial, testicular, and penile. The review highlights mutations in DNA damage repair genes, such as BRCA1/2 and PTEN, as well as pathway alterations like FGFR and PD-L1 overexpression. These mutations influence tumor behavior and therapeutic outcomes, emphasizing the need for precision oncology approaches. Molecular profiling, through tools like next-generation sequencing, has revolutionized patient care by enabling targeted treatment strategies, especially in cancers with distinct molecular subtypes such as luminal or basal bladder cancer and clear cell renal carcinoma. Emerging therapies, including FGFR inhibitors and immune checkpoint blockade, offer new treatment avenues, although resistance mechanisms remain a challenge. We also emphasize the importance of biomarker identification for personalized management, especially in metastatic settings where treatment intensification is often required. Future research is needed to further elucidate our understanding of the genetics affecting urologic cancers, which will help develop novel, individualized therapies to enhance oncologic outcomes.

27 July 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
ADArthur Drouaud
Arthur Drouaud
VXVincent Eric Xu
Vincent Eric Xu
AVAlejandro Velasquez
Alejandro Velasquez
RARyan Antar
Ryan Antar
BBBrandon Boyarsky
Brandon Boyarsky
MWMichael Whalen
Michael Whalen

2 May 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
RARyan M. Antar
Ryan M. Antar
VXVincent Eric Xu
Vincent Eric Xu
OAOluwafolajimi Adesanya
Oluwafolajimi Adesanya
ADArthur Drouaud
Arthur Drouaud
NLNoah Longton
Noah Longton
MWMichael Whalen
Michael Whalen
Background: Muscle-invasive bladder cancer (MIBC) is a potentially fatal disease, especially in the setting of locally advanced or node-positive disease. Adverse outcomes have also primarily been associated with low-income status, as has been reported in other cancers. While the adoption of neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy (RC) and pelvic lymph node dissection (PLND) has improved outcomes, these standard-of-care treatments may be underutilized in lower-income patients. We sought to investigate the economic disparities in NAC and PLND receipt and survival outcomes in MIBC. Methods: Utilizing the National Cancer Database, a retrospective cohort analysis of cT2-4N0-3M0 BCa patients with urothelial histology who underwent RC was conducted. The impact of income level on overall survival (OS) and the likelihood of receiving NAC and PLND was evaluated. Results: A total of 25,823 patients were included. This study found that lower-income patients were less likely to receive NAC and adequate PLND (≥15 LNs). Moreover, lower-income patients exhibited worse OS (Median OS 55.9 months vs. 68.2 months, p < 0.001). Our findings also demonstrated that higher income, treatment at academic facilities, and recent years of diagnosis were associated with an increased likelihood of receiving standard-of-care modalities and improved survival. Conclusions: Even after controlling for clinicodemographic variables, income independently influenced the receipt of standard MIBC treatments and survival. Our findings identify an opportunity to improve the quality of care for lower-income MIBC patients through concerted efforts to regionalize multi-modal urologic oncology care.

1 October 2024 in JBJS Open Access
Verified
Journal Article
Open access
ADArthur Drouaud
Arthur Drouaud
CSCarolina Stocchi
Carolina Stocchi
JTJustin Tang
Justin Tang
GGGrant Gonsalves
Grant Gonsalves
ZCZoe Cheung
Zoe Cheung
DFDavid Forsh
David Forsh
Introduction: We assessed ChatGPT-4 vision (GPT-4V)'s performance for image interpretation, diagnosis formulation, and patient management capabilities. We aim to shed light on its potential as an educational tool addressing real-life cases for medical students. Methods: Ten of the most popular orthopaedic trauma cases from OrthoBullets were selected. GPT-4V interpreted medical imaging and patient information, providing diagnoses, and guiding responses to OrthoBullets questions. Four fellowship-trained orthopaedic trauma surgeons rated GPT-4V responses using a 5-point Likert scale (strongly disagree to strongly agree). Each of GPT-4V's answers was assessed for alignment with current medical knowledge (accuracy), rationale and whether it is logical (rationale), relevancy to the specific case (relevance), and whether surgeons would trust the answers (trustworthiness). Mean scores from surgeon ratings were calculated. Results: In total, 10 clinical cases, comprising 97 questions, were analyzed (10 imaging, 35 management, and 52 treatment). The surgeons assigned a mean overall rating of 3.46/5.00 to GPT-4V's imaging response (accuracy 3.28, rationale 3.68, relevance 3.75, and trustworthiness 3.15). Management questions received an overall score of 3.76 (accuracy 3.61, rationale 3.84, relevance 4.01, and trustworthiness 3.58), while treatment questions had an average overall score of 4.04 (accuracy 3.99, rationale 4.08, relevance 4.15, and trustworthiness 3.93). Conclusion: This is the first study evaluating GPT-4V's imaging interpretation, personalized management, and treatment approaches as a medical educational tool. Surgeon ratings indicate overall fair agreement in GPT-4V reasoning behind decision-making. GPT-4V performed less favorably in imaging interpretation compared with its management and treatment approach performance. The performance of GPT-4V falls below our fellowship-trained orthopaedic trauma surgeon's standards as a standalone tool for medical education.

17 September 2024 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
VXVincent Eric Xu
Vincent Eric Xu
OAOluwafolajimi Adesanya
Oluwafolajimi Adesanya
SASarah Azari
Sarah Azari
SISamita Islam
Samita Islam
MKMatthew Klein
Matthew Klein
MWMichael Whalen
Michael Whalen